According to e-healthme, a reporting site which is based on reports by the FDA and self-reporting of actual patients, on May 22, 2013--
90,168 people reported to have side effects when taking Tysabri.
Among them, 665 people (0.74%) have died.
http://www.ehealthme.com/ds/tysabri/death
359 people are currently reported to have PML.
http://chefarztfrau.de/?page_id=716

But there have been more Tysabri deaths documented, linked to antibody reactions, lethal ...

Unfortunately the Tysabri related cases of PML have jumped 12 from last month bringing the new total to 359. Don't know if there has been any additional deaths. It isn't getting any better.

http://chefarztfrau.de/?page_id=716

Harry

Has anyone had current or recent experience with PML?
Whom, in addition to Biogen, should be contacted for consultation for PML management and treatment?
Who are the expert doctors in this field?
My nephew is currently hospitalized and getting his second session of plasma exchange for PML treatment. He was on Tysabri for five years and was just diagnosed with PML.
Thank you.

Just took my blood test to find out if I have the JC virus(hope I spelled right). If I am negative, the neurologist strongly recommends Tysabri. If I am positive, then they want to go with Avonex. Being the positive person that I am at 35, I'm thinking I am gonna be negative. So anyone out there in this MS world want to tell me their experience with Tysabri? Anything I should prepare for? I ...

Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue.

Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue. The TYNERGY study aimed to further evaluate the effects of natalizumab treatment on MS-related fatigue...... Read More - http://www.ms-uk.org/index.cfm/tysabri

Biogen Idec gains commercial rights of Tysabri from Elan Corporation

Biogen Idec has completed its purchase of Elan Corporation’s interest in Tysabri (natalizumab) and has gained full strategic, commercial and decision-making rights of Tysabri. The transaction was originally announced on February 6, 2013....................Read More - http://www.ms-uk.org/index.cfm/tysabri

New Tysabri And Anti-JCV Antibody Stability Data Released

Biogen Idec and Elan Corporation, plc announced results from several studies of Tysabri(R) (natalizumab) that demonstrate its efficacy compared to other multiple sclerosis (MS) treatments, provide additional data supporting anti-JC virus (JCV) antibody status stability, and suggest better outcomes when progressive multifocal leukoencephalopathy (PML) is detected early. These data will be presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego.........Read ...

Early Magnetic Resonance Detection of Natalizumab-Related Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Sclerosis

Diagnosis of progressive multifocal leukoencephalopathy is usually based on the clinical presentation, on the demonstration of the brain lesions at the magnetic resonance imaging examination, and on the detection of the JC virus DNA in the cerebrospinal fluid with high sensitive polymerase chain reaction..... Read More - http://www.ms-uk.org/index.cfm/tysabri

Early Detection of MS Treatment Complication May Improve Survival

The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology’s 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. ...

Taking Gilenya after stopping Tysabri doesn't suppress MS reactivation
http://www.overcomingmultiplesclerosis. ... ctivation/